Axsome Therapeutics (AXSM) Scheduled to Post Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSM) is set to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($1.36) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Axsome Therapeutics Stock Down 0.7 %

Shares of NASDAQ:AXSM opened at $90.07 on Friday. The company has a market capitalization of $4.28 billion, a price-to-earnings ratio of -13.84 and a beta of 1.26. The company has a 50 day moving average of $90.31 and a two-hundred day moving average of $83.53. Axsome Therapeutics has a 52-week low of $55.02 and a 52-week high of $98.40. The company has a quick ratio of 2.40, a current ratio of 2.48 and a debt-to-equity ratio of 1.77.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, September 5th. Needham & Company LLC reissued a “buy” rating and set a $130.00 price target on shares of Axsome Therapeutics in a research report on Thursday, September 5th. Wells Fargo & Company initiated coverage on shares of Axsome Therapeutics in a report on Tuesday, September 3rd. They issued an “overweight” rating and a $140.00 price target on the stock. Bank of America raised shares of Axsome Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $95.00 to $106.00 in a report on Tuesday, August 6th. Finally, StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $124.64.

Insider Buying and Selling

In other Axsome Therapeutics news, Director Mark E. Saad sold 11,016 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the sale, the director now directly owns 10,002 shares in the company, valued at approximately $913,282.62. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 22.40% of the stock is owned by company insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.